clear space
Overview Line Executive Management Line Scientific Advisory Board Line Business Advisory Board Line Contact

Scientific Advisory Board

Daniel D. Von Hoff, M.D., F.A.C.P.

Senior Advisor, Clinical Development
In the past three decades, Dr. Von Hoff has been fundamental in the development and approval of agents such as gemcitabine, fludarabine, paclitaxel, docetaxel, topotecan, irinotecan, mitoxantrone, and nab-paclitaxel. He is currently Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen), Professor of Medicine at the Mayo Clinic, and the Chief Scientific Officer of Scottsdale Healthcare and US Oncology. Dr. Von Hoff is a former member of the FDA's Oncology Drug Advisory Committee (ODAC) and served on President Bush's National Cancer Advisory Board. He was previously the Director of the Arizona Cancer Center and former president of the American Association of Cancer Research (AACR). He is a past member of the Board of Scientific Advisors of the National Cancer Institute, as well as a former board member of the American Society of Clinical Oncology (ASCO). Dr. Von Hoff co-founded ILEX Oncology, Inc. in 1993, which was later acquired by Genzyme Corp. in 2004. Dr. Von Hoff has authored more than 529 papers, 129 book chapters, and 891 abstracts, has edited the Cancer Chemotherapy Handbook and has seats on the editorial board of 12 scientific journals, including the founding and current Editor-in-Chief of Molecular Cancer Therapeutics. Dr. Von Hoff also currently acts as Co-Team Leader for the Stand Up to Cancer (SU2C) Dream Team focused on developing new agents targeting pancreatic cancer.

Laurence H. Hurley, Ph.D.

Advisor, Howard J. Schaeffer Endowed Chair in Pharmaceutical Sciences, The University of Arizona, Tucson
Dr. Laurence Hurley is the Howard Schaeffer Endowed Chair in Pharmaceutical Sciences in the College of Pharmacy at the University of Arizona and has led an internationally renowned research program spanning a period of over 40 years at several first-tier research universities in the United States. Prior to his present position, he was the George H. Hitchings Regents Chair in Drug Design at the University of Texas at Austin. He has published over 250 research publications in top-tier journals, including Science, Nature, Proceedings of the National Academy of Science USA, Journal of the American Chemical Society, Journal of Medicinal Chemistry, and Journal of Biological Chemistry and has an H-index of 61. Dr. Hurley is the recipient of numerous awards that have recognized his contributions to the pharmaceutical industry. He is also the recipient of a number of lectureships, including the 2001 Frank Rose Memorial Lecture at the British Association for Cancer Research; the Thirtieth Mary E. Kapp Lecturer in Chemistry, Virginia Commonwealth University (2007); and the Hecht Lecturer at University of Virginia (2012).

Randall T. Peterson, Ph.D.

Advisor, Associate Professor at Harvard Medical School
Dr. Peterson received his doctorate from Harvard University after studying as a Howard Hughes Medical Institute predoctoral fellow in the laboratory of Professor Stuart L. Schreiber. Following graduation, he completed a postdoctoral fellowship with Professor Mark Fishman at Massachusetts General Hospital. Dr. Peterson is currently Assistant Professor of Medicine at Harvard Medical School, Associate Member of the Broad Institute of MIT and Harvard, and Director of the Chemical Biology Program at MGH. Dr. Peterson has pioneered the use of zebrafish for small molecule discovery, is inventor on numerous patents.

clear space